SpringWorks Therapeutics Inc

NASDAQ:SWTXUnited States

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. It has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. Its product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI), in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.

Contact Information

Headquarters

100 Washington BlvdSTAMFORD, CT, United States 06902-9302

Phone

203-883-9490

Fax

302-655-5049

Executives

Independent Chairman of the Board

Daniel Lynch

Chief Executive Officer, Director

Saqib Islam

Chief Financial Officer

Francis Perier

Chief Operating Officer

Badreddin Edris

Chief People Officer

Daniel Pichl